ViaCyte’s expanding intellectual property portfolio enables the development of therapies in areas beyond the Company’s current focus in diabetes. For example, ViaCyte’s hESC technology could be optimal for cell-based screening of candidate pharmaceutical compounds. The Encaptra® drug delivery system could be used in the development of products for life sciences research. ViaCyte welcomes the exploration of research and business opportunities. Please contact us for further information.